Taku Shigesawa

Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1–3 signaling, but not FGFR4 signaling

Taku Shigesawa, Osamu Maehara, Goki Suda et al. · Carcinogenesis · 2020 · 75 citations · Full text

Medicine, Oncology, Pharmacology +16

Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection

Kazuharu Suzuki, Goki Suda, Yoshiya Yamamoto et al. · Journal of Gastroenterology · 2020 · 61 citations

Life Sciences, Biochemistry, Pharmacology +13

Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people

Masatsugu Ohara, Goki Suda, Megumi Kimura et al. · Hepatology Research · 2020 · 48 citations

Medicine, Radiology, Biomedical Imaging +12

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting

Takuya Sho, Goki Suda, Koji Ogawa et al. · JGH Open · 2019 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan

Takashi Kitagataya, Goki Suda, Kazunori Nagashima et al. · Journal of Gastroenterology and Hepatology · 2020 · 45 citations · Full text

Life Sciences, Immunology, Oncology +14